HeartSciences Inc. Faces Delisting Concerns

TL;DR

HSCS might get delisted - big trouble ahead.

AI Summary

HeartSciences Inc. filed an 8-K on September 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as Heart Test Laboratories, Inc., is incorporated in Texas and has its principal executive offices in Southlake, Texas.

Why It Matters

This filing indicates potential issues with HeartSciences Inc.'s continued listing on an exchange, which could significantly impact its stock value and trading liquidity.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and investor confidence.

Key Players & Entities

• HeartSciences Inc. (company) — Registrant
• September 16, 2025 (date) — Earliest event reported
• September 17, 2025 (date) — Date of report
• Texas (location) — State of incorporation
• Southlake, Texas (location) — Principal executive offices
• Heart Test Laboratories, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $2.5 million — Capital Market to maintain a minimum of $2.5 million in stockholders' equity (the "Minimum S

Filing Documents

• hscs-20250916.htm (8-K) — 44KB
• 0001193125-25-206295.txt ( ) — 181KB
• hscs-20250916.xsd (EX-101.SCH) — 45KB
• hscs-20250916_htm.xml (XML) — 6KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 16, 2025, HeartSciences Inc. (the "Company") received formal notice from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained compliance with Nasdaq's Minimum Stockholders' Equity Requirement (as defined below) and the matter is now closed. As previously disclosed in the Company's Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on March 21, 2025, the Company previously received a letter from the Staff indicating that the Company was not in compliance with the requirements of Nasdaq Listing Rule 5550(b)(1) (the "Rule"), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity (the "Minimum Stockholders' Equity Requirement"), and the Company did not otherwise meet the alternative requirements of market value of listed securities or net income from continuing operations, for continued listing on The Nasdaq Capital Market. The Company subsequently submitted with Nasdaq a specific plan to regain and sustain compliance with the Rule. Based on the Company's submission, the Staff previously granted the Company an extension of time to regain compliance with the Rule.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEARTSCIENCES INC. Date: September 17, 2025 By: /s/ Andrew Simpson Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors

View Full Filing

View this 8-K filing on SEC EDGAR